Automated Inhaler Monitoring for Asthma Medication Usage

Automated Inhaler Monitoring for Asthma Medication Usage

The goal of this clinical trial is to evaluate the aflo™ digital platform's ability to improve inhaler use technique and asthma control for children, adolescents, and adults with uncontrolled asthma. The main questions the trial aims to answer are:

1. Does the platform improve medication adherence and inhaler technique, as measured by the Inhaler Proficiency Score (IPS)?
2. Does the aflo™ platform improve asthma control, as measured by changes in the Asthma Control Test (ACT) and lung function tests (FEV1, PEF)?

Participants will:

• Use the aflo™ sensor with their asthma inhaler to receive real-time feedback on technique and medication adherence reminders.
• Track asthma symptoms and quality of life through a mobile app.
• Complete assessment visits and surveys at the start and end of the 3-month study and 2 interim asthma assessment phone calls.

Inclusion Criteria:

1. Youth or adult with a diagnosis of persistent asthma by a physician.
2. Evidence of uncontrolled asthma as defined by an FEV1/FVC ratio of less than 80% by an asthma provider within the past 3 months, all while on controller asthma therapy.
3. Females or males between the ages of 10 years and older
4. Participant or caregiver must have an Apple and/or Android smart phone with operating system 4.3 or above and data plan for the duration of the study period

Exclusion Criteria:

1. Participants with other cardiac, pulmonary with exception of asthma, neuromuscular disorders that impact breathing, or other conditions that hinder patient to perform spirometry.
2. Participants with severe neurobehavioral, neurodevelopmental, or psychiatric disorders requiring special assistance
3. The participant's guardian or the patient has comprehension or language difficulties that prevent understanding of study materials (available in English) or effective training on the app or device.
4. Patients are currently receiving biologic therapies for asthma management or other allergic diseases.